We examined the role of total body magnetic resonance imaging (TB-MRI)-governed involved compartment irradiation (ICI) and high-dose chemotherapy (HDC), followed by stem cell rescue (SCR) in patients with high-risk Ewing tumors (ETs) with multiple primary bone metastases (high-risk ET-MBM). Eleven patients with high-risk ET-MBM receiving initial assessment of involved bones by TB-MRI were registered from 1995 to 2000 (group A). In all, 6 patients out of 11 had additional lung disease at initial diagnosis; all had multifocal bone disease with more than three bones involved. After systemic induction with etoposide, vincristine, adriamycin (doxorubicin), ifosfamide, and actinomycin D (EVAIA) or VAIA chemotherapy, ICI of all sites positive by TB-MRI was administered, followed by HDC and SCR. A second group matched for observation period and consisting of 26 patients with more than three involved bones at diagnosis was treated with the European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol (group B). These patients did not receive TB-MRI and consequently did not receive TB-MRI-governed ICI, or HDC and SCR. Survival in group A vs group B was 45 vs 8% at 5 years and 27 vs 8% at 10 years after diagnosis (log rank and Breslow: Po0.005). We conclude that TB-MRIgoverned ICI followed by HDC and SCR in ET-MBM is feasible and warrants further evaluation in prospective studies.
Introduction
Ewing tumors (ETs) may originate from transformed primitive neural crest-derived progenitor cells at transition to mesenchymal and endothelial differentiation. [1] [2] [3] [4] [5] They are defined by a reciprocal chromosomal t(11;22)(q24;q12) translocation and the expression of ews/ets fusion genes, which permit a specific molecular genetic diagnosis of ET. 6, 7 ET requires risk-adapted treatment and stage is the main risk factor. Prognosis of ET metastasis at initial diagnosis is highly dependent on the site of metastasis: although patients with isolated pulmonary metastases have a prognosis of X50% event-free survival at 3 years with appropriate therapy, including lung irradiation with agedependent doses, 8 prognosis of patients with bone and BM metastases is almost uniformly fatal, with p10% survival at 10 years. 9 This extremely poor prognosis applies for patients with high-risk multiple primary bone metastases (high-risk ET-MBM) alone or in combination with pulmonary disease. High-risk ET-MBM may well respond to therapy, but recurrent disease is frequent. 10 Several studies have shown that chemotherapy is highly capable of controlling micrometastatic disease. 11, 12 Meanwhile, it is generally accepted that even high-dose chemotherapy (HDC) is insufficient to control macrometastatic (macroscopic) disease. However, local therapy, that is, irradiation and/or surgery, can control macroscopic disease. Previous studies have addressed the question whether HDC can control primary multifocal ET. [13] [14] [15] [16] The results of these studies are controversial. A carefully controlled study has recently shown that HDC alone may not improve the prognosis of patients with primary multifocal ET. 17 A study has also shown that total body magnetic resonance imaging (TB-MRI) is more sensitive than the conventionally used 99m technetium methylene diphosphonate bone scintigraphy scan for detection of metastatic bones in primary multifocal ET. 18 On the basis of these findings, we examined the role of TB-MRIgoverned involved compartment irradiation (ICI) followed by melphalan/etoposide (ME)-based HDC in combination with stem cell rescue (SCR) in high-risk ET-MBM patients in a retrospective study. We compared this group of patients with patients recruited from the European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) registry who did not receive TB-MRI-governed ICI followed by ME-based HDC in combination with SCR, but whose therapy was otherwise comparable.
Patients and methods

Patient characteristics
Patients with more than three involved bones were classified as bearing high-risk ET-MBM. These patients were treated either with a treatment plan consisting of TB-MRI, HDC and SCR in addition to the EICESS-92 study (Meta-EICESS) or with the treatment plan of the EICESS-92 study alone. Patients for the latter group were recruited from the EICESS-92 registry. The former group of patients was termed 'group A' and the latter group was termed 'group B'. Assignment of patients to group A was done by referral to Meta-EICESS participating institutions (Du¨sseldorf, Hamburg, Essen and Oldenburg). Group B patients were retrospectively identified. They had not received TB-MRI for logistic reasons, that is, because of their remote residence from Meta-EICESS centers. Both groups were matched for early progression before the start of ICI, that is, within the first 12 weeks.
In group A, 11 patients with high-risk ET-MBM at diagnosis (aged 6-32 years; median: 16 years) were registered in the participating institutions from 1995 to 2000 and treated according to the TandemME (n ¼ 9) or the HyperME (n ¼ 2) Meta-EICESS treatment plans as previously described. 19, 20 A respective treatment overview is shown in Figure 1 . All 11 patients received TB-MRI as a part of the initial staging procedure. All were diagnosed with multifocal bone disease with more than three bones involved, 2 out of 11 patients had lymph node metastases (LN) and 6 out of 11 had lung disease at initial diagnosis. Detailed characteristics are given in Tables 1 and 2 . The data of these patients have been published previously with short-term follow-up. 19, 20 In group B, 26 patients with more than three bones involved at diagnosis (aged 6-37 years; median: 17 years) were registered from 1992 to 1996 and treated according to the European Intergroup Cooperative Ewing Sarcoma Study 92 protocol (EICESS 92) for high-risk ET-MBM, as previously described. 21 In all, 1 out of 26 patients had LN metastases and 10 out of 26 patients had lung disease at initial diagnosis. Group B patients did not receive TB-MRI at staging, and thus did not receive TB-MRI-governed ICI. Furthermore, these patients did not receive HDC and SCR.
All patients or their legal guardians signed informed consent prior to therapy. Protocol treatment was applied after approval by the institutional review boards according to the precepts established by the Helsinki Conference Declaration.
Initial staging
In group A patients, the stage and extent of disease were evaluated by BM aspirates, technetium scintigraphy bone scans and TB-MRI. For TB-MRI, short tau (time) inversion recovery imaging was applied in all patients. Lung disease was assessed by thoracic computed tomography. MRI and technetium bone scans were evaluated and reviewed side by side. In group B patients, extent and stage of disease were evaluated by tumor MRI, chest computed tomography, BM aspirates and technetium scintigraphy bone scans.
Induction chemotherapy, myeloablative chemotherapy and local treatment In group A, 2 out of 11 patients were treated with VAIA (VCR, adriamycin (doxorubicin), ifosfamide and actinomycin D) and 9 out of 11 patients with E/VAIA (additional etoposide) as induction chemotherapy and local intensification with ICI parallel to the last two cycles of chemotherapy. Myeloablative therapy consisted of high-dose melphalan Â 2 (total dose 120-140 mg/m 2 body surface) and etoposide (60 mg/kg, maximum: 1800 mg/m 2 body surface). Out of 11 patients, 9 patients received only autologous SCR and 2 patients received autologous followed by allogeneic SCR. Autologous stem cells (1.8 Â 10 6 -15 Â 10 6 CD34 þ cells/kg) were given on day 0. In 2 out of 11 patients receiving additional allogeneic SCR, conditioning therapy consisted of BU (4 Â 1 mg/kg) and CY (60 mg/kg) (matched related donor) or BU and fludarabine (matched unrelated donor), respectively. The former mentioned patient received allogeneic SCR owing to the occurrence of secondary malignancy and the latter received allogeneic SCR because of progression after initial autologous SCR. Myeloid reconstitution was augmented by granulocyte colony stimulating factor (5 mg/kg) until a neutrophil count 41000 cells/ml was reached. In group A, local treatment was administered before myeloablative therapy and consisted of ICI therapy ( Figure 1 ).
In detail, group A patients received the following ICI treatment: bones: maximum 54 Gy (2 Â 1,6 Gy per day) on sites with short tau (time) inversion recovery imaging signal in initial MRI; vertebrae and rib cage: up to 40 Gy; lungs: 12-18 Gy (age dependent), 2 Â 1,2 Gy per day. Actinomycin or adriamycin was not given during irradiation. Consolidation with DoubleME or HyperME was carried out 4-6 weeks after last EVAI/A. Radiation dose as indicated above was given in two series parallel to chemotherapy cycles 5 and 6. The median delay of chemotherapy was approximately 1 week as compared with chemotherapy cycles without radiation. Low blood cell counts did not lead to interruption of treatment.
In 1 out of 11 surviving patients, a late lung metastasis was resected (Table 1 , patient number 1). As regards chemotherapy in group B, 20 out of 26 patients received only EVAIA and 6 out of 26 patients received VAIA followed by EVAIA. With local therapy, 7 out of 26 patients received surgery, 18 out of 26 patients received technetium methylene diphosphonate bone scan-governed irradiation of tumor sites and 6 out of 26 patients received both surgery and irradiation. The total irradiation dose in group B was 40-54 Gy, wherein the bone dose was 54 Gy, except for 40 Gy for spine if more than three vertebrae were involved.
Statistical analysis
OS time was defined as the interval between the date of initial diagnosis and date of last follow-up or death. The P-value of OS was determined by the Kaplan-Meier method using the Statistical Package for Social Science (SPSS, Chicago, IL, USA), version 16.0. Group comparisons were made using the log rank and Breslow tests, wherein Po0.05 were considered statistically significant.
Results
Eleven group A patients with high-risk ET-MBM were treated from 1995 to 2000 according to the Meta-EICESS protocols as previously described 19, 20 ( Figure 1 ). These patients received ICI on the basis of TB-MRI at initial staging. The median OS from diagnosis was 6 years (range: 6 months-14 years). Out of 11 patients, 3 were alive at the end of the follow-up period and 8 patients had died, of whom 3 succumbed to death from complications (DFC) and 5 died from disease (DFD) ( Tables 1 and 2 ). Grade III-IV treatment-related toxicity, according to the National Cancer Institute Toxicity Criteria (version 2.0), was present in all group A patients. Of 3 out of 11 patients who had succumbed to DFC, 2 patients died of treatment-related secondary malignancies (liposarcoma and myelodysplastic syndrome) and 1 patient died of treatment-related bacterial sepsis. In the latter 2 out of 3 patients mentioned to have died of secondary malignancies, the liposarcoma emerged in the radiation field and the myelodysplastic syndrome originated in the patient, respectively, as the patient belonged to the sub-group that had received only autologous SCR. Both patients who had been additionally treated with allogeneic SCR developed fatal grade III-IV graft-vs-host disease (Tables 1 and 2) .
In group B, 26 patients were registered from 1992 to 1996 and treated according to the EICESS 92 protocol as previously described. 21 The median OS was 1 year (range 0.5-14 years). Out of 26 patients, 2 were alive at the end of the follow-up period and 24 patients had died, of whom 22 patients succumbed to DFD and 2 patients succumbed to DFC. Of the latter 2 out of 24 patients, 1 patient developed treatment-related secondary malignancy that led to DFC. Grade III-IV treatment related toxicity in group B was present in 18 out of 26 (69%) patients ( Table 2) .
Incidence of DFC was 3 out of 11 (27%) in group A compared with 2 out of 26 patients (8%) in group B. The difference was NS (P ¼ 0.131; Fisher's exact test).
Survival of group A vs group B was 45% (5 out of 11) vs 8% (2 out of 26) at 5 years and 27% (3 out of 11) vs 8% (2 out of 26) at 10 years after diagnosis. Comparing the outcome of the 11 group A patients with ICI on the basis of I.
II. vincristine, adriamycin (doxorubicin), ifosfamide, actinomycin D; ME, melphalan, etoposide; Tc, technetium; PCR, polymerase chain reaction; CT, computer tomography; TB-MRI, total body magnetic resonance imaging; PB, peripheral blood; and BM, bone marrow. Allogeneic transplantation due to progression (patient 4) and secondary malignancy (patient 10).
c Liposarcoma emerged in the radiation field. /l; infection, serious infection, with or without hypotonia; oral mucositis, ulcerations and/or impossible food intake; diarrhea, requiring treatment; bilirubin, 45 Â normal; alanine transaminases (ALTs) and/or aspartate transaminases (ASTs), 45 Â normal; central neurotoxicity, unbearable paresthesia, motoric loss of function or paralysis; cardiotoxicity, temporary fractional shortening o28%; skin, ulceration, moist desquamation, exfoliative dermatitis or necrosis.
TB-MRI at initial staging with the outcome of the 26 group B patients without initial TB-MRI-governed ICI, HDC and SCR, OS was significantly higher in group A (log rank and Breslow: Po0.005; Figure 2 ).
Discussion
We investigated the OS of ET patients with primary multiple bone metastases receiving ICI therapy on the basis of a TB-MRI as initial staging in comparison with an appropriate group of patients who did not receive such treatment. Our hypothesis was that ICI therapy based on initial staging with TB-MRI leads to an improved outcome. We found an improved OS in 11 high-risk ET-MBM patients who underwent TB-MRI-governed ICI and HDC followed by SCR (group A) as compared with 26 high-risk ET-MBM patients who did not undergo TB-MRIgoverned ICI and HDC followed by SCR (group B). The P-value of OS at 10 years was 27% in group A vs 8% in group B (Po0.01). In group A, grade III-IV treatmentrelated toxicity was significantly higher. Furthermore, DFC, mainly due to treatment-related secondary malignancies, was also higher in this group without reaching statistical significance.
In contrast to most patients in group B, patients in group A were treated after 1995. Hence, medical progress, in particular, in supportive therapy, may have contributed to the improved prognosis in group A. Such limitations are characteristic for many studies in high-risk ET-MBM. 17 Successful treatment of high-risk ET-MBM needs both systemic chemotherapy and local control. Our data suggest that TB-MRI may facilitate precise identification of initial metastases in high-risk ET-MBM and that sufficient ICI may decrease the relapse rate.
The prognosis for patients with metastatic ET at diagnosis is clearly worse than for patients without metastases. 22 Moreover, the site of metastases also has a great impact: several studies have shown a better prognosis for patients with ET metastasis to the lungs compared with patients suffering from ET with metastases to extrapulmonary sites: Patients with bone metastases had a significantly (Po0.001) poorer prognosis (5-year RFS 19%) than patients with lung metastases (5-year RFS 29%). Finally, within the high-risk group of patients with primary multifocal bone or BM disease, a higher number of involved bones worsened the prognosis: no patient with more than one bone or with BM metastasis survived in this study. 10, 20 Taken together, metastatic ETs are heterogeneous, and even within ET-MBM prognosis may vary depending on the number of involved bones. In this study, we addressed patients with more than one (multiple) metastatic bone, with or without BM metastases at diagnosis. These patients were defined as having ET-MBM.
Whether the introduction of HDC and SCR has improved prognosis in primary bone metastatic disease in general, and in patients with multiple bone metastases in particular, is still a matter of debate. 23 Kushner and Meyers 24 analyzed 21 unselected patients with ET metastasis to the bone or BM. Survival was 10% at 2 years and 5% at 3 years. There was one long-term eventfree survivor. Out of 21 patients, 10 patients received local irradiation. Detailed information regarding the extent of radiation of metastatic sites was not reported. In all, 10 patients succumbed to DFD before SCR, 7 to DFD after SCR and 3 to DFC after SCR. Event-free survival was not improved compared with the literature. In 2001, Meyers et al. 17 published a further report focusing on patients with bone or BM metastases. Out of 32 patients with high-risk ET-MBM, 23 patients were transplanted after induction therapy with CY, doxorubicin and VCR alternating with ifosfamide and etoposide and myeloablative therapy with melphalan, etoposide and TBI. Event-free survival was 24%, and that for all eligible patients was 20% 2 years after SCR. The outcome of the transplanted group was not superior to a historical group without HDC and SCR. MRI was only used for imaging of the primary tumor and not sites of metastasis. Local therapy consisted of irradiation to sites of metastasis, and in patients in whom a high number of sites could be detected, irradiation was given to those sites with inferior response to induction therapy. The majority of transplanted patients succumbed to DFD.
High-dose chemotherapy alone may well be insufficient to control multiple disease sites in a disease that is characterized by the fact that HDC and SCR cannot replace definitive local therapy in single-site disease. Local treatment is complicated by the fact that the disease has a systemic component that needs to be treated simultaneously: that is, cessation of chemotherapy during radiotherapy may lead to progression outside the radiation field. Thus, combined radiochemotherapy has to be applied during local intensification. Identification and treatment of all involved sites is important in improving long-term survival and cure. Hence, accurate staging may have a great impact on prognosis. The existing methods for initial staging are conventional radiography, technetium methylene diphosphonate bone scintigraphy, computed tomography scans, MRI and, more recently, fluor-desoxy glucose positron emission tomography. All these methods are able to detect skeletal metastases but have limitations. Ongoing studies suggest that MRI can detect metastases at an earlier stage than radiography, scintigraphy or computed tomography. Short tau (time) inversion recovery imaging allows more precise depiction of tumors than spinecho sequences. [25] [26] [27] [28] Several studies comparing scintigraphy with MRI have demonstrated that MRI is more sensitive and more specific than scintigraphy, [29] [30] [31] [32] but to date there are few reports available assessing the potential of TB-MRI. 33 Eustace et al. 34 compared TB-MRI and scintigraphy in detecting skeletal metastases in 49 patients with solid tumors. MRI was superior to scintigraphy.
Extensive total body imaging with detection of an increased number of involved bones and compartments leads to extensive irradiation fields with up to 50% of total marrow volume exposed. These extensive fields and volumes may be tolerated in combination with SCR.
Our study was based on the concept that high-risk ET-MBM require three sequential therapeutic modalities: (1) systemic induction by conventional chemotherapy, (2) local intensification by combined radiochemotherapy in conjunction with SCR and (3) systemic consolidation by tandem-HDC with SCR. We suggest that TB-MRIgoverned ICI in combination with HDC and SCR in high-risk ET-MBM is feasible and warrants further evaluation in prospective studies.
Survival in group A patients is relatively high, but is still insufficient and late relapses do occur. However, therapy in this study is short, compared with the less advanced stages, and mutilating surgery can be avoided. Nevertheless, development of novel therapies for this group of patients is still warranted.
